Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600
Debt
Debt-to-Equity RatioN/A
Current Ratio2.85
Quick Ratio2.85
Price-To-Earnings
Trailing P/E Ratio-6.62
Forward P/E Ratio-6.16
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.61 million
Price / Sales577.45
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book7.15
Profitability
EPS (Most Recent Fiscal Year)($2.81)
Net Income$-128,980,000.00
Net MarginsN/A
Return on Equity-103.24%
Return on Assets-81.36%
Miscellaneous
Employees154
Outstanding Shares49,850,000
Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions
What is Karyopharm Therapeutics' stock symbol?
Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."
How were Karyopharm Therapeutics' earnings last quarter?
Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced its quarterly earnings data on Thursday, May, 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.11. The company had revenue of $10 million for the quarter, compared to analyst estimates of $4.59 million. View Karyopharm Therapeutics' Earnings History.
When is Karyopharm Therapeutics' next earnings date?
What price target have analysts set for KPTI?
9 brokerages have issued 12-month price targets for Karyopharm Therapeutics' shares. Their predictions range from $18.00 to $30.00. On average, they expect Karyopharm Therapeutics' share price to reach $21.7778 in the next twelve months. View Analyst Ratings for Karyopharm Therapeutics.
What are Wall Street analysts saying about Karyopharm Therapeutics stock?
Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
- 1. HC Wainwright analysts commented, "We believe this data bodes well for the ongoing Phase 3 BOSTON trial, for which top-line data is expected in 2019. We note that standard Vd regimens (control arm of BOSTON) have an ORR of 60-65% and PFS of 7-9 months according to previous studies. More positive data in the selinexor in the STOMP SDd arm. In the combination selinexor, Darzalex, and low dose dex (SDd) arm evaluating MM patients who received at least three prior lines of therapy, including a PI and an immunomodulatory drug (IMiD), or patients with MM refractory to both a PI and an IMiD, the ORR was 74% (n=19) with an ORR of 82% in Darzalex naïve patients (n=17) in evaluable patients as of June 5, 2018. This is relatively in line with prior data, as of for eight Darzalex naïve patients, with an ORR of 88%." (6/15/2018)
- 2. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (5/17/2018)
- 3. Cantor Fitzgerald analysts commented, "KPTI reported top-line STORM data, which demonstrated a 25.4% ORR (2 CRs and 19 PRs) and 4.4 months DoR in penta-refractory myeloma patients. That means the company will be able to file an NDA for accelerated approval in this population in the U.S. and Europe." (4/30/2018)
- 4. Canaccord Genuity analysts commented, "We had the pleasure of hosting Karyopharm CEO Michael Kauffman and CFO Mike Falvey for meetings with institutional investors in New York City. Overall, investors focused on upcoming and potentially registration-supporting datasets for lead drug candidate selinexor in two trials: STORM in penta-refractory multiple myeloma (April 30) and SADAL in relapsed/refractory diffuse large B-cell lymphoma (DLBCL, 2H). We came away with increased confidence that Accelerated Approval is a viable path for selinexor, continue to view the available data as indicative of benefit, and reiterate our BUY rating and $22 PT." (4/10/2018)
Who are some of Karyopharm Therapeutics' key competitors?
Some companies that are related to Karyopharm Therapeutics include Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Clovis Oncology (CLVS) and Xencor (XNCR).
Who are Karyopharm Therapeutics' key executives?
Karyopharm Therapeutics' management team includes the folowing people:
- Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 55)
- Dr. Sharon Shacham, Co-Founder, Co-Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer (Age 48)
- Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 37)
- Dr. Mansoor Raza Mirza, Clinical Consultant, Director and Member of Scientific Advisory Board (Age 57)
- Mr. Michael F. Falvey, Exec. VP, CFO & Treasurer (Age 59)
Has Karyopharm Therapeutics been receiving favorable news coverage?
Headlines about KPTI stock have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Karyopharm Therapeutics earned a daily sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the company an impact score of 46.07 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Karyopharm Therapeutics' major shareholders?
Karyopharm Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (7.38%), BlackRock Inc. (5.55%), Franklin Resources Inc. (4.13%), Point72 Asset Management L.P. (3.93%), venBio Select Advisor LLC (1.12%) and Northern Trust Corp (0.80%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.
Which institutional investors are selling Karyopharm Therapeutics stock?
KPTI stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Franklin Resources Inc., Candriam Luxembourg S.C.A., Iguana Healthcare Management LLC, Opus Point Partners Management LLC, A.R.T. Advisors LLC and JPMorgan Chase & Co.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.
Which institutional investors are buying Karyopharm Therapeutics stock?
KPTI stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Doheny Asset Management CA, Palo Alto Investors LP, BlackRock Inc., Prudential Financial Inc., Trexquant Investment LP, Cubist Systematic Strategies LLC and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Karyopharm Therapeutics.
How do I buy shares of Karyopharm Therapeutics?
Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Karyopharm Therapeutics' stock price today?
One share of KPTI stock can currently be purchased for approximately $18.57.
How big of a company is Karyopharm Therapeutics?
Karyopharm Therapeutics has a market capitalization of $929.70 million and generates $1.61 million in revenue each year. The company earns $-128,980,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Karyopharm Therapeutics employs 154 workers across the globe.
How can I contact Karyopharm Therapeutics?
Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]
MarketBeat Community Rating for Karyopharm Therapeutics (KPTI)
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
